Annexon, Inc. current report, 20 December 2023

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Annexon, Inc. on December 20, 2023. The filing discloses material events regarding the Company's clinical development programs for two lead candidates: ANX007 for geographic atrophy (GA) and ANX1502 for Cold Agglutinin Disease (CAD).

Key Financial Metrics

This filing is a Current Report (Form 8-K) and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The text explicitly states that the Company may need additional capital to complete its clinical trials but does not provide specific liquidity figures or current debt levels.

Material Changes and Clinical Updates

ANX007 (Geographic Atrophy)

  • Regulatory Alignment: The Company announced alignment with the FDA on using vision preservation (prevention of ≥15-letter loss of BCVA) as the primary endpoint for its global registrational program, removing the requirement for a surrogate structural endpoint.
  • ARCHER II Trial: A global sham-controlled Phase 3 trial designed to confirm Phase 2 results. Expected to initiate in mid-2024 with topline data anticipated in the second half of 2026. Enrolling approximately 400 patients.
  • ARROW Trial: A head-to-head Phase 3 trial comparing ANX007 against SYFOVRE® (pegcetacoplan). Expected to initiate in late 2024, contingent on EMA approval of SYFOVRE® in Europe. Topline data anticipated mid-2027. Enrolling approximately 500 patients.

ANX1502 (Cold Agglutinin Disease)

  • Phase 1 Results: Reported results from single and multiple ascending dose studies in healthy volunteers. The drug was generally well-tolerated with no serious adverse events.
  • Pharmacokinetics: Achieved target serum levels and demonstrated dose-proportional PK. Suppressed C4d serum levels (a biomarker of complement activation) at doses of 525 mg to 1025 mg.
  • Next Steps: The Company intends to advance a tablet formulation into a proof-of-concept study in CAD patients, expected to initiate in 2024.

    • Outlook, Risks, and Contingencies

    • Regulatory Risk: The FDA may not accept data from the ARCHER II sham-controlled trial alone for U.S. approval, necessitating the ARROW head-to-head trial. There is no assurance that ARROW data will be sufficient for approval.
    • Comparator Challenges: Conducting the ARROW trial against SYFOVRE® presents risks, including potential difficulties in patient recruitment due to existing FDA-approved therapies, delays in obtaining the comparator drug, and the lack of historical BCVA data for SYFOVRE® to aid in trial powering.
    • Capital Requirements: The global two-trial program is described as expensive and time-consuming. The Company explicitly notes it may need to raise additional capital to complete these trials, with no guarantee of timely funding.
    • Timeline Risks: Clinical trials may not be conducted as planned or completed timely, which could delay or prevent commercialization.

    Investor Verification Checklist

    • Verify the Company's current cash runway and ability to fund the ARCHER II and ARROW trials without immediate dilution.
    • Monitor the timeline for EMA approval of SYFOVRE® in Europe, which is a prerequisite for initiating the ARROW trial.
    • Track patient enrollment rates for both Phase 3 trials, given the competitive landscape of existing GA therapies.
    • Review the safety profile of ANX1502 as it moves from healthy volunteers to CAD patients in 2024.
    • Confirm FDA feedback on the ARROW trial design to ensure the head-to-head comparison will be accepted for regulatory approval.